Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Harvard Business School
US Department of Justice
Argus Health

Generated: January 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021225

« Back to Dashboard

NDA 021225 describes MIRENA, which is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the MIRENA profile page.

The generic ingredient in MIRENA is levonorgestrel. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.
Summary for 021225
Applicant:Bayer Hlthcare
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Pharmacology for NDA: 021225
Ingredient-typeProgesterone Congeners
Physiological EffectInhibit Ovum Fertilization
Medical Subject Heading (MeSH) Categories for 021225
Suppliers and Packaging for NDA: 021225
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MIRENA levonorgestrel INTRAUTERINE DEVICE;INTRAUTERINE 021225 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-423 50419-423-01 1 INTRAUTERINE DEVICE in 1 CARTON (50419-423-01)
MIRENA levonorgestrel INTRAUTERINE DEVICE;INTRAUTERINE 021225 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-423 50419-423-08 1 INTRAUTERINE DEVICE in 1 CARTON (50419-423-08)

Profile for product number 001

Approval Date:Dec 6, 2000TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Sep 16, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Apr 1, 2031Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.